Modus Therapeutics Holding
1.16 SEK +7.41%Be the first to follow this company
Modus Therapeutics operates in the biotechnology industry. The product portfolio is broad and includes, for example, sevuparin. The company's focus is to develop sevuparin for patients with sepsis / septic shock, a serious and often fatal condition. In addition to the main business, service and associated ancillary services are also offered. The activities with associated research are conducted in Sweden.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
MODTX
Daily low / high price
1.1 / 1.25
SEK
Market cap
41.69M SEK
Turnover
54.73K SEK
Volume
49K
Financial calendar
Interim report
2024-08-23
Interim report
2024-11-20
Annual report
2025-02-20
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Karolinska Development AB | 66.1 % | 66.1 % |
KDev Investments AB | 7.7 % | 7.7 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Annual General Meeting in Modus Therapeutics Holding AB (publ)
Penser Future by Carnegie: Modus Therapeutics Holding: Förberedelsefas inför kliniska fas IIa-studier
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools